Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.
Identifieur interne : 003036 ( Main/Exploration ); précédent : 003035; suivant : 003037Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.
Auteurs : Nicolas Girerd [France] ; Tim Collier [Royaume-Uni] ; Stuart Pocock [Royaume-Uni] ; Henry Krum [Australie] ; John J. Mcmurray [Royaume-Uni] ; Karl Swedberg [Royaume-Uni] ; Dirk J. Van Veldhuisen [Pays-Bas] ; John Vincent [États-Unis] ; Bertram Pitt [États-Unis] ; Faiez Zannad [France]Source :
- European heart journal [ 1522-9645 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Antagonistes des récepteurs des minéralocorticoïdes (usage thérapeutique), Défaillance cardiaque systolique (mortalité), Défaillance cardiaque systolique (traitement médicamenteux), Femelle, Hospitalisation (), Humains, Hyperkaliémie (), Mâle, Prévention secondaire, Réadmission du patient, Résultat thérapeutique, Spironolactone (analogues et dérivés), Spironolactone (usage thérapeutique), Sujet âgé, Syndrome coronarien aigu (), Syndrome coronarien aigu (mortalité), Études de suivi.
- MESH :
- analogues et dérivés : Spironolactone.
- mortalité : Défaillance cardiaque systolique, Syndrome coronarien aigu.
- traitement médicamenteux : Défaillance cardiaque systolique.
- usage thérapeutique : Antagonistes des récepteurs des minéralocorticoïdes, Spironolactone.
- Adulte d'âge moyen, Femelle, Hospitalisation, Humains, Hyperkaliémie, Mâle, Prévention secondaire, Réadmission du patient, Résultat thérapeutique, Sujet âgé, Syndrome coronarien aigu, Études de suivi.
English descriptors
- KwdEn :
- Acute Coronary Syndrome (mortality), Acute Coronary Syndrome (prevention & control), Aged, Female, Follow-Up Studies, Heart Failure, Systolic (drug therapy), Heart Failure, Systolic (mortality), Hospitalization (statistics & numerical data), Humans, Hyperkalemia (chemically induced), Male, Middle Aged, Mineralocorticoid Receptor Antagonists (therapeutic use), Patient Readmission, Secondary Prevention, Spironolactone (analogs & derivatives), Spironolactone (therapeutic use), Treatment Outcome.
- MESH :
- chemical , analogs & derivatives : Spironolactone.
- chemical , therapeutic use : Mineralocorticoid Receptor Antagonists, Spironolactone.
- chemically induced : Hyperkalemia.
- drug therapy : Heart Failure, Systolic.
- mortality : Acute Coronary Syndrome, Heart Failure, Systolic.
- prevention & control : Acute Coronary Syndrome.
- statistics & numerical data : Hospitalization.
- Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Patient Readmission, Secondary Prevention, Treatment Outcome.
Abstract
Cardiovascular hospitalization (CVH) in patients with heart failure (HF) is associated with a high post-discharge rate of early re-admission and CV death. Eplerenone might be effective in reducing the incidence of these adverse clinical outcomes during this period.
DOI: 10.1093/eurheartj/ehv273
PubMed: 26093641
Affiliations:
- Australie, France, Pays-Bas, Royaume-Uni, États-Unis
- Angleterre, Grand Est, Grand Londres, Groningue (province), Lorraine (région), Michigan, Victoria (État), Écosse, État de New York
- Glasgow, Groningue, Londres, Melbourne, Nancy, Vandoeuvre lès Nancy
- Université de Glasgow, Université de Lorraine
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002A22
- to stream PubMed, to step Curation: 002952
- to stream PubMed, to step Checkpoint: 002952
- to stream Ncbi, to step Merge: 002732
- to stream Ncbi, to step Curation: 002732
- to stream Ncbi, to step Checkpoint: 002732
- to stream Main, to step Merge: 003037
- to stream Main, to step Curation: 003036
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.</title><author><name sortKey="Girerd, Nicolas" sort="Girerd, Nicolas" uniqKey="Girerd N" first="Nicolas" last="Girerd">Nicolas Girerd</name><affiliation wicri:level="4"><nlm:affiliation>INSERM, Centre D'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu, 4 Rue du Morvan, 54500 Vandoeuvre lès Nancy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, Centre D'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu, 4 Rue du Morvan, 54500 Vandoeuvre lès Nancy</wicri:regionArea><wicri:noRegion>54500 Vandoeuvre lès Nancy</wicri:noRegion><orgName type="university">Université de Lorraine</orgName><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Collier, Tim" sort="Collier, Tim" uniqKey="Collier T" first="Tim" last="Collier">Tim Collier</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Pocock, Stuart" sort="Pocock, Stuart" uniqKey="Pocock S" first="Stuart" last="Pocock">Stuart Pocock</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name><affiliation wicri:level="3"><nlm:affiliation>Center of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Center of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Mcmurray, John J" sort="Mcmurray, John J" uniqKey="Mcmurray J" first="John J" last="Mcmurray">John J. Mcmurray</name><affiliation wicri:level="4"><nlm:affiliation>The British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name><affiliation wicri:level="3"><nlm:affiliation>Department of Molecular and Clinical Medicine, University of Gothenburg, Goteborg, Sweden National Heart and Lung Institute, Imperial College, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Molecular and Clinical Medicine, University of Gothenburg, Goteborg, Sweden National Heart and Lung Institute, Imperial College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J" last="Van Veldhuisen">Dirk J. Van Veldhuisen</name><affiliation wicri:level="3"><nlm:affiliation>Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Vincent, John" sort="Vincent, John" uniqKey="Vincent J" first="John" last="Vincent">John Vincent</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name><affiliation wicri:level="2"><nlm:affiliation>School of Medicine, University of Michigan, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Medicine, University of Michigan, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name><affiliation wicri:level="4"><nlm:affiliation>INSERM, Centre D'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu, 4 Rue du Morvan, 54500 Vandoeuvre lès Nancy, France f.zannad@chu-nancy.fr.</nlm:affiliation><country wicri:rule="url">France</country><wicri:regionArea>INSERM, Centre D'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu, 4 Rue du Morvan, 54500 Vandoeuvre lès Nancy</wicri:regionArea><placeName><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region><settlement type="city">Vandoeuvre lès Nancy</settlement><settlement type="city">Nancy</settlement></placeName><orgName type="university">Université de Lorraine</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26093641</idno><idno type="pmid">26093641</idno><idno type="doi">10.1093/eurheartj/ehv273</idno><idno type="wicri:Area/PubMed/Corpus">002A22</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A22</idno><idno type="wicri:Area/PubMed/Curation">002952</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002952</idno><idno type="wicri:Area/PubMed/Checkpoint">002952</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002952</idno><idno type="wicri:Area/Ncbi/Merge">002732</idno><idno type="wicri:Area/Ncbi/Curation">002732</idno><idno type="wicri:Area/Ncbi/Checkpoint">002732</idno><idno type="wicri:Area/Main/Merge">003037</idno><idno type="wicri:Area/Main/Curation">003036</idno><idno type="wicri:Area/Main/Exploration">003036</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.</title><author><name sortKey="Girerd, Nicolas" sort="Girerd, Nicolas" uniqKey="Girerd N" first="Nicolas" last="Girerd">Nicolas Girerd</name><affiliation wicri:level="4"><nlm:affiliation>INSERM, Centre D'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu, 4 Rue du Morvan, 54500 Vandoeuvre lès Nancy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, Centre D'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu, 4 Rue du Morvan, 54500 Vandoeuvre lès Nancy</wicri:regionArea><placeName><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region><settlement type="city">Vandoeuvre lès Nancy</settlement><settlement type="city">Nancy</settlement></placeName><orgName type="university">Université de Lorraine</orgName></affiliation></author><author><name sortKey="Collier, Tim" sort="Collier, Tim" uniqKey="Collier T" first="Tim" last="Collier">Tim Collier</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Pocock, Stuart" sort="Pocock, Stuart" uniqKey="Pocock S" first="Stuart" last="Pocock">Stuart Pocock</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name><affiliation wicri:level="3"><nlm:affiliation>Center of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Center of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Mcmurray, John J" sort="Mcmurray, John J" uniqKey="Mcmurray J" first="John J" last="Mcmurray">John J. Mcmurray</name><affiliation wicri:level="4"><nlm:affiliation>The British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name><affiliation wicri:level="3"><nlm:affiliation>Department of Molecular and Clinical Medicine, University of Gothenburg, Goteborg, Sweden National Heart and Lung Institute, Imperial College, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Molecular and Clinical Medicine, University of Gothenburg, Goteborg, Sweden National Heart and Lung Institute, Imperial College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J" last="Van Veldhuisen">Dirk J. Van Veldhuisen</name><affiliation wicri:level="3"><nlm:affiliation>Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Vincent, John" sort="Vincent, John" uniqKey="Vincent J" first="John" last="Vincent">John Vincent</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name><affiliation wicri:level="2"><nlm:affiliation>School of Medicine, University of Michigan, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Medicine, University of Michigan, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name><affiliation wicri:level="4"><nlm:affiliation>INSERM, Centre D'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu, 4 Rue du Morvan, 54500 Vandoeuvre lès Nancy, France f.zannad@chu-nancy.fr.</nlm:affiliation><country wicri:rule="url">France</country><wicri:regionArea>INSERM, Centre D'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu, 4 Rue du Morvan, 54500 Vandoeuvre lès Nancy</wicri:regionArea><placeName><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region><settlement type="city">Vandoeuvre lès Nancy</settlement><settlement type="city">Nancy</settlement></placeName><orgName type="university">Université de Lorraine</orgName></affiliation></author></analytic><series><title level="j">European heart journal</title><idno type="eISSN">1522-9645</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute Coronary Syndrome (mortality)</term><term>Acute Coronary Syndrome (prevention & control)</term><term>Aged</term><term>Female</term><term>Follow-Up Studies</term><term>Heart Failure, Systolic (drug therapy)</term><term>Heart Failure, Systolic (mortality)</term><term>Hospitalization (statistics & numerical data)</term><term>Humans</term><term>Hyperkalemia (chemically induced)</term><term>Male</term><term>Middle Aged</term><term>Mineralocorticoid Receptor Antagonists (therapeutic use)</term><term>Patient Readmission</term><term>Secondary Prevention</term><term>Spironolactone (analogs & derivatives)</term><term>Spironolactone (therapeutic use)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Antagonistes des récepteurs des minéralocorticoïdes (usage thérapeutique)</term><term>Défaillance cardiaque systolique (mortalité)</term><term>Défaillance cardiaque systolique (traitement médicamenteux)</term><term>Femelle</term><term>Hospitalisation ()</term><term>Humains</term><term>Hyperkaliémie ()</term><term>Mâle</term><term>Prévention secondaire</term><term>Réadmission du patient</term><term>Résultat thérapeutique</term><term>Spironolactone (analogues et dérivés)</term><term>Spironolactone (usage thérapeutique)</term><term>Sujet âgé</term><term>Syndrome coronarien aigu ()</term><term>Syndrome coronarien aigu (mortalité)</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Spironolactone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Mineralocorticoid Receptor Antagonists</term><term>Spironolactone</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Spironolactone</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hyperkalemia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Heart Failure, Systolic</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Acute Coronary Syndrome</term><term>Heart Failure, Systolic</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Défaillance cardiaque systolique</term><term>Syndrome coronarien aigu</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Acute Coronary Syndrome</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Défaillance cardiaque systolique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antagonistes des récepteurs des minéralocorticoïdes</term><term>Spironolactone</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Patient Readmission</term><term>Secondary Prevention</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Femelle</term><term>Hospitalisation</term><term>Humains</term><term>Hyperkaliémie</term><term>Mâle</term><term>Prévention secondaire</term><term>Réadmission du patient</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Syndrome coronarien aigu</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cardiovascular hospitalization (CVH) in patients with heart failure (HF) is associated with a high post-discharge rate of early re-admission and CV death. Eplerenone might be effective in reducing the incidence of these adverse clinical outcomes during this period.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Grand Est</li><li>Grand Londres</li><li>Groningue (province)</li><li>Lorraine (région)</li><li>Michigan</li><li>Victoria (État)</li><li>Écosse</li><li>État de New York</li></region><settlement><li>Glasgow</li><li>Groningue</li><li>Londres</li><li>Melbourne</li><li>Nancy</li><li>Vandoeuvre lès Nancy</li></settlement><orgName><li>Université de Glasgow</li><li>Université de Lorraine</li></orgName></list><tree><country name="France"><region name="Grand Est"><name sortKey="Girerd, Nicolas" sort="Girerd, Nicolas" uniqKey="Girerd N" first="Nicolas" last="Girerd">Nicolas Girerd</name></region><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Collier, Tim" sort="Collier, Tim" uniqKey="Collier T" first="Tim" last="Collier">Tim Collier</name></region><name sortKey="Mcmurray, John J" sort="Mcmurray, John J" uniqKey="Mcmurray J" first="John J" last="Mcmurray">John J. Mcmurray</name><name sortKey="Pocock, Stuart" sort="Pocock, Stuart" uniqKey="Pocock S" first="Stuart" last="Pocock">Stuart Pocock</name><name sortKey="Swedberg, Karl" sort="Swedberg, Karl" uniqKey="Swedberg K" first="Karl" last="Swedberg">Karl Swedberg</name></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name></region></country><country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J" last="Van Veldhuisen">Dirk J. Van Veldhuisen</name></region></country><country name="États-Unis"><region name="État de New York"><name sortKey="Vincent, John" sort="Vincent, John" uniqKey="Vincent J" first="John" last="Vincent">John Vincent</name></region><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003036 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003036 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26093641
|texte= Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26093641" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |